Crescent Biopharma, Inc.CBIONASDAQ
Loading
Cost of Revenue Over TimeExpanding
Percentile Rank100
3Y CAGR+17.7%
5Y CAGR+12.1%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
+17.7%/yr
vs +39.2%/yr prior
5Y CAGR
+12.1%/yr
Recent acceleration
Acceleration
-21.4pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
1.8x
Solid growth
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $1.68M | +4687.6% |
| 2024 | $35174.00 | -77.1% |
| 2023 | $153301.00 | -85.1% |
| 2022 | $1.03M | - |
| 2021 | $0.00 | -100.0% |
| 2020 | $951599.00 | +5.8% |
| 2019 | $899302.00 | +226.9% |
| 2018 | $275123.00 | +4.4% |
| 2017 | $263541.00 | - |
| 2016 | $0.00 | - |